Document is current
Any future updates will be listed below
-
Authors
Takeishi, Shoichiro https://orcid.org/0000-0003-1640-909X
Marchand, Tony
Koba, Wade R.
Borger, Daniel K. https://orcid.org/0000-0001-8055-019X
Xu, Chunliang
Guha, Chandan
Bergman, Aviv https://orcid.org/0000-0002-6340-2125
Frenette, Paul S.
Gritsman, Kira https://orcid.org/0000-0002-1367-1167
Steidl, Ulrich https://orcid.org/0000-0002-9458-1795
- License Information
-
More Information
Article History
Received: 27 August 2023
Accepted: 28 July 2025
First Online: 27 August 2025
Competing interests
: T.M. serves as a consultant for Astellas, Jazz Pharmaceuticals, Servier and Sobi, and has received personal fees from Jazz Pharmaceuticals and Servier outside the submitted work. C.G. has received grants and personal fees from Janssen and Varian, and grants from Celldex outside the submitted work. P.S.F. served as a consultant for Pfizer, received research funding from Ironwood Pharmaceuticals outside the submitted work, and was a shareholder of Cygnal Therapeutics. K.G. has received research funding from ADC Therapeutics and iOnctura outside the submitted work. U.S. has received grants from GlaxoSmithKline, Bayer Healthcare, Aileron Therapeutics and Novartis, and personal fees from GlaxoSmithKline, Bayer Healthcare, Celgene, Aileron Therapeutics, Stelexis Therapeutics, Pieris Pharmaceuticals, Trillium and Pfizer outside the submitted work. U.S. has equity ownership in and has served on the board of directors of Stelexis Therapeutics outside the submitted work. U.S. has equity ownership in Roshon Therapeutics outside the submitted work. The other authors declare no competing interests.
